Research Topics
| Nezam H AfdhalSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Hepatitis C pharmacogenetics: state of the art in 2010Nezam H Afdhal
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
Hepatology 53:336-45. 2011....
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled studyNezam H Afdhal
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Gastroenterology 126:1302-11. 2004..This study assessed whether epoetin alfa could maintain RBV dose, improve quality of life (QOL), and increase hemoglobin (Hb) in anemic HCV-infected patients...- The natural history of hepatitis CNezam H Afdhal
Medical Director, Liver Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Semin Liver Dis 24:3-8. 2004..Progression of liver disease in 20 to 30% of patients can lead to compensated and eventually decompensated cirrhosis or hepatocellular carcinoma, or both. This article looks briefly at the epidemiology and natural history of hepatitis C... 
Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitisMiroslaw Kornek
Harvard Medical School, Boston, MA, USA
Gastroenterology 143:448-58. 2012..Patients with nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH) can be differentiated from those with CHC based on activation of distinct sets of immune cells in the liver...- Duration of peginterferon therapy in acute hepatitis C: a randomized trialSanaa M Kamal
Department of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
Hepatology 43:923-31. 2006..Duration of treatment should be further optimized based on genotype and rapid virologic response at week 4... - Use of growth factors with antiviral therapy for chronic hepatitis CMichael P Curry
Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA
Clin Liver Dis 9:439-51, vii. 2005.... - Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesisShaoyong Li
Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
Hepatology 56:2094-105. 2012.... - Role of epoetin alfa in maintaining ribavirin doseNezam H Afdhal
Department of Medicine, Liver Center, Beth Israel Deaconess Medical Center, 110 Francis Street, Suite 8E, Boston, MA 02215, USA
Gastroenterol Clin North Am 33:S25-35. 2004.... - Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis CPaul J Pockros
Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
Hepatology 46:324-9. 2007..Longer studies to assess potential effects of IDN-6556 on liver inflammation and fibrosis are merited... - Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United StatesLaren Becker
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Clin Gastroenterol Hepatol 7:696-701. 2009..Hepascore uses noninvasive serum markers and has been validated in Australian and European populations for predicting different degrees of fibrosis. This study validated this test in a U.S. population... - Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosisSanaa M Kamal
Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Hepatology 43:771-9. 2006..In conclusion, serial cytokine and fibrosis markers can accurately determine the rate at which fibrosis is progressing, identifying both those with rapid fibrosis and those with stable disease... - Diagnosis and quantitation of fibrosisDiarmuid S Manning
Beth Israel Deaconess Medical Center, Boston, Massachusetts, and Harvard Medical School, Boston, Massachusetts, USA
Gastroenterology 134:1670-81. 2008..This article reviews the current role of liver biopsy in the assessment of hepatic fibrosis and discusses the role of the newer noninvasive methods including serum markers and radiologic tests... - Overexpression of estrogen receptor alpha increases hepatic cholesterogenesis, leading to biliary hypersecretion in miceHelen H Wang
Department of Medicine, Liver Center and Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard Digestive Diseases Center, Boston, MA, USA
J Lipid Res 47:778-86. 2006..These studies provide insights into therapeutic approaches to cholesterol gallstones in high-risk subjects, especially those exposed to high levels of estrogen... - Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA indexThomas B Kelleher
Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 8E, Boston, MA 02215, USA
J Hepatol 43:78-84. 2005..CONCLUSIONS: Amongst HIV/HCV co-infected patients, serum testing for HA, albumin, and AST (SHASTA Index) was able to accurately stage mild and advanced fibrosis... - Antiviral therapy for treatment naïve patients with hepatitis C virusSangik Oh
Department of Medicine, Harvard Medical School, 25 Shattack Street, Boston, MA 02115, USA
Gastroenterol Clin North Am 33:497-511, viii. 2004..Recent data suggest that an SVR can be equated with a biochemical, virological,and histological response that is sustained for up to 5 years and is conceptually a cure of HCV in 90% of patients... - Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both?Nezam H Afdhal
Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
JAMA 308:608-16. 2012..Improved noninvasive diagnostic tests, a clearer understanding of the natural history of NAFLD, and large, well-designed clinical trials are needed... - Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognitionValerie Byrnes
Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
J Hepatol 56:549-56. 2012..We aimed to evaluate the effect of pegylated interferon/ribavirin (PIFN/R) and HCV clearance on cerebral metabolism, and neuropsychological performance... - Therapeutic strategies for chronic hepatitis B virus infection in 2008Asim Khokhar
Liver Research Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Am J Med 121:S33-44. 2008..Long-term studies indicate that effective suppression of viral replication improves clinical outcome, with improvement of liver histology and, it is assumed, a decreased risk for development of hepatocellular carcinoma... - Lith genes and genetic analysis of cholesterol gallstone formationHelen H Wang
Liver Center and Gastroenterology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Gastroenterol Clin North Am 39:185-207, vii-viii. 2010.... - Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic miceHelen H Wang
Department of Medicine, Liver Center and Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard Digestive Diseases Center, Boston, Massachusetts 02215, USA
Gastroenterology 131:210-22. 2006..The gel-forming mucins play an important role in the early stage of cholesterol gallstone formation. We investigated whether the gallbladder epithelial mucin encoded by mucin gene 1 (MUC1) influences susceptibility to gallstones... - Liver cirrhosisDetlef Schuppan
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Lancet 371:838-51. 2008..This Seminar focuses on the diagnosis, complications, and management of cirrhosis, and new clinical and scientific developments... - The clinical significance of persistently normal ALT in chronic hepatitis B infectionMichelle Lai
Beth Israel Deaconess Medical Center, Division of Hepatology, Harvard Medical School, Boston, MA, USA
J Hepatol 47:760-7. 2007..The role of ALT levels as a predictor of liver injury has recently been questioned. The aim of the study was to determine whether normal ALT is associated with liver injury in a cohort of HBV patients undergoing liver biopsy... - The clinical outcome of small (<20 mm) arterially enhancing nodules on MRI in the cirrhotic liverValerie Byrnes
Department of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Am J Gastroenterol 102:1654-9. 2007..To evaluate the outcome of arterially enhancing nodules (AENs) measuring <20 mm detected on MRI in patients with cirrhosis... - The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitisDetlef Schuppan
Beth Israel Deaconess Medical Center, Division of Gastroenterology, Harvard Medical School, Boston, MA 02215, USA
Liver Int 30:795-808. 2010..Combined with a better understanding of the pathophysiological processes that underlie the mechanisms of hepatic fibrogenesis in NASH, rapid clinical validation of novel therapies is expected... - Ultrasound-based hepatic elastography: origins, limitations, and applicationsEric B Cohen
Yale University School of Medicine, Department of Digestive Diseases, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Clin Gastroenterol 44:637-45. 2010..HE is now being used in lieu of liver biopsy to investigate the natural history of chronic liver diseases. Additional studies are required to better define the appropriate role of HE in clinical practice... - Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic responseSanaa M Kamal
Division of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Gastroenterology 130:632-8. 2006..Initiation of treatment at week 8 or 12 results in higher sustained virologic rates than initiation at week 20... - Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cellsMiroslaw Kornek
Division of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
Hepatology 53:230-42. 2011..CONCLUSION: Circulating T cell MPs are a novel diagnostic marker for inflammatory liver diseases, and in vivo induction of T cell MPs may be a novel strategy to induce regression of liver fibrosis... - Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver diseaseNoah T Zinkin
Liver Center, Department of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115, USA
Clin Cancer Res 14:470-7. 2008.... - Evaluation of liver fibrosis: a concise reviewNezam H Afdhal
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02125, USA
Am J Gastroenterol 99:1160-74. 2004..The limitations of utilization of these markers for both cross-sectional diagnosis of fibrosis and monitoring disease progression or regression are discussed... - Eltrombopag before procedures in patients with cirrhosis and thrombocytopeniaNezam H Afdhal
Division of Gastroenterology Liver Center, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
N Engl J Med 367:716-24. 2012.... - Hemodynamic effects of substance P and its receptor antagonist RP67580 in anesthetized rats with carbon tetrachloride-induced cirrhosisAndres Cardenas
Liver Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
Scand J Gastroenterol 43:328-33. 2008..The aim of this study was to determine the effects of SP (dose--13 pg/kg) and its specific inhibitor, RP67580 (dose--300 microg/kg) on mean arterial pressure (MAP) and portal pressure (PP) in cirrhotic rats and controls... - Editorial: staging liver fibrosis in hepatitis C: a challenge for this decadeMichelle Lai
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Am J Gastroenterol 106:2121-2. 2011..Am J Gastroenterol 2011; 106:2121-2122; doi:10.1038/ajg.2011.343... - Estrogen receptor alpha, but not beta, plays a major role in 17beta-estradiol-induced murine cholesterol gallstonesHelen H Wang
Department of Medicine, Liver Center and Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard Digestive Diseases Center, Boston, Massachusetts 02215, USA
Gastroenterology 127:239-49. 2004..Our findings may offer a new approach to treat gallstones by inhibiting hepatic ER activity with a liver-specific, ERalpha-selective antagonist... - Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genesDavid Q-H Wang
Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, DA 601, Boston, MA 02215, USA
Curr Gastroenterol Rep 6:140-50. 2004..Because exceptionally close homology exists between mouse and human genomes, the orthologous human LITH genes can often be recognized after mouse genes are identified... - Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis CKeyur Patel
Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
Clin Gastroenterol Hepatol 6:242-7. 2008..We hypothesized that a noninvasive test of liver fibrosis can accurately stage liver fibrosis. We prospectively evaluated the FIBROSpect II (FSII) biomarker panel versus pathology assessment and a quantitative measure of fibrosis... - Management of hepatitis C virus in special populations: patient and treatment considerationsRobert G Gish
Liver Transplant Program and Division of Hepatology and Complex GI, California Pacific Medical Center, 2340 Clay Street 232, San Francisco, CA 94115, USA
Clin Gastroenterol Hepatol 3:311-8. 2005..Close monitoring and management of therapeutic side effects are required to assist these patients in adhering to therapy... - Iron, HCV, and liver cancer: hard metal setting the pace?Sebastian Mueller
Gastroenterology 130:2229-34. 2006 - Race, insulin resistance and hepatic steatosis in chronic hepatitis CHari S Conjeevaram
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
Hepatology 45:80-7. 2007..Insulin resistance but not steatosis was independently associated with lower sustained virological response... - Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapyPaul J Pockros
Scripps Clinic, La Jolla, CA 92037, USA
Hepatology 40:1450-8. 2004..Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy... - Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis CGamal Esmat
National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
J Hepatol 46:620-7. 2007..We evaluated whether surrogate serum biomarkers for liver injury are comparable to liver biopsy in Egyptian patients with hepatitis C virus (HCV) infection... - Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysisZachary D Goodman
Armed Forces Institute of Pathology, Division of Hepatic Pathology, Veterans Administration Special Reference Laboratory for Pathology, Washington, DC, USA
Hepatology 45:886-94. 2007..CONCLUSION: In advanced chronic hepatitis C, fibrosis increases at a rapid pace that can only be detected by morphometry. This technique can be used in future therapeutic trials of agents to inhibit fibrosis progression... - Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virusJohn G McHutchison
ALT Alliance for Liver Therapy Group, Division of Gastroenterology and Hepatology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Hepatology 46:1341-9. 2007..The data support further clinical studies of CPG 10101 for treating chronic HCV infection... - Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis CJohn G McHutchison
Duke University and Duke Clinical Research Institute, Durham, NC 27705, USA
N Engl J Med 357:2227-36. 2007..We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia associated with HCV-related cirrhosis... - Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adultsMark S Sulkowski
Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
AIDS 21:2209-16. 2007.... - Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosisNezam H Afdhal
J Hepatol 46:543-5. 2007 - Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis?Nezam H Afdhal
Clin Chem 50:1299-300. 2004 - Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests?Nezam H Afdhal
Hepatology 37:972-4. 2003 - Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virusMark S Sulkowski
Division of Infectious Diseases Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
AIDS 19:585-92. 2005.... - The not so good effects of nitric oxide inhibition with methylene blue in cirrhosis and ascitesAndres Cardenas
Dig Dis Sci 52:939-40. 2007